B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

SCN3A

MOLECULAR TARGET

sodium voltage-gated channel alpha subunit 3

UniProt: Q9NY46NCBI Gene: 632823 compounds

SCN3A (sodium voltage-gated channel alpha subunit 3) is targeted by 23 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SCN3A

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Flunarizine Flunarizine is1.614
2Lacosamide1.393
3Saxitoxin1.102
4Mianserin0.691
5Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent0.691
6Bupivacaine0.691
7Chlorpheniramine0.691
8Cinnarizine0.691
9Cyproheptadine0.691
10Dextromethorphan Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of0.691
11Dibucaine0.691
12dilazep0.691
13Etidocaine0.691
14Hydroxyzine0.691
15lidoflazine0.691
16Nortriptyline0.691
17Phenobarbital0.691
18Phentolamine0.691
19Promethazine0.691
20protriptyline0.691
21Quinidine0.691
22Reserpine0.691
23Veratridine0.691

About SCN3A as a Drug Target

SCN3A (sodium voltage-gated channel alpha subunit 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 23 compounds with documented SCN3A interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SCN3A inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.